TheEdgeResearch
Home / Stocks / MSCLF

Satellos Bioscience Inc. (MSCLF)

OTC Healthcare Biotechnology
$6.25 ▲ +11.81%
Market Cap
$96.6M
Sector
Healthcare
Industry
Biotechnology
Beta
0.71
52-Wk Range
0.88-12.5
CEO
Francis Gleeson
Country
CA
Currency
USD

Satellos Bioscience Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Toronto, ON, CA. The stock last traded at $6.25, up 11.81% on the session, giving a market capitalisation of $96.6M. On trailing twelve-month figures it carries a trailing P/E of -0.80, a net margin of 0.0%. Its beta of 0.71 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-0.80
Price / Sales
0.00
Price / Book
0.27
EV / EBITDA
-4.75
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
—
Debt / equity
0.00
Current ratio
7.77
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
14
IPO date
2012-08-03
Headquarters
Toronto, ON, CA
About Satellos Bioscience Inc.

Satellos Bioscience Inc., a biotechnology firm established in 2018 and headquartered in Toronto, Canada, specializes in developing regenerative therapies for degenerative muscle diseases. The company primarily operates in Canada and Australia, utilizing its proprietary MyoReGenX platform – an automated microscopy system engineered to replicate the muscle stem cell environment outside the body. A key focus for Satellos is the discovery and development of a small molecule drug specifically aimed at treating Duchenne muscular dystrophy.

Comparable companies

Satellos Bioscience Inc. is most often compared with the following Healthcare names:

BSEMHSCHFIUGNFKNTPFPBIGFPOLBFPRNAFSPHRYTOKIFVSBC
More research on MSCLF
MSCLF technical analysis MSCLF TheEdge Score Compare against peers
Open full interactive analysis & DCF →